glp 1 agonist drugs for weight loss The New Management Meds GLP-1 Weight Loss Medications Explained:

The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials

GLP-2 and GIP exert separate effects on bone turnover: A randomised, placebo-controlled, crossover study in healthy young men

The right choice depends on individual eligibility, tolerability, comorbidities, preferences, and accessnot on averages alone

Coming from high-dose tirzepatide specifically

On average, volunteers in the retatrutide clinical trial who received the study drug rather than a placebo lost an average of 70.3 pounds over about a year-and-a-half, with more than 45% of participants losing more than 30% of their body weight

How to Screen GLP-1 Drug Manufacturers Which current and future GLP-1 manufacturers may be best-positioned to navigate these risks